Supplied formTwo-component peptide material: linear BPC-157 15-mer plus full-length N-acetylated thymosin-β4 (TB-500, 43 residues)
Lead time14–21 days
Representative packaging image · verify the ordered lot
Decision summary
Key benefits
Research applications include component-specific analytical qualification, controlled comparison of two preclinical repair-pathway hypotheses and development of methods that resolve both peptides in one matrix
The pairing is useful only when the experimental design includes each component alone, vehicle controls and a prespecified interaction analysis.
Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.
Qualification data
Specifications to confirm against the released lot
CAS
Confirm per batch COA
Formula
Confirm supplied form on batch COA
Molecular weight
Confirm supplied form on batch COA
Appearance
Lot- and presentation-specific lyophilized research material; confirm whether components are separate or co-presented and verify the released appearance for each
Purity
Component-specific identity, chromatographic purity and quantitative content; a single blended purity value is insufficient · target, verify batch COA
Storage
Use only the released-lot COA, SDS and stability statement for the actual presentation. If separate, qualify each component independently; if co-presented, require mixture-specific stability, compatibility, concentration, matrix, container and hold-time evidence. Do not apply a generic 2–8°C or 30-day rule.
MOQ
1 kit (10 vials) per SKU
Lead time
14–21 days
Qualification matrix
Identity, purity and content are separate release questions.
Identity
Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.
Purity
Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.
Content
Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.
Stability
Follow the storage condition stated on the batch COA or label from receipt onward.
Research context
What researchers study about BPC-157 + TB-500 (Wolverine Stack)
This catalogue name refers to BPC-157, the linear 15-mer GEPPPGKPADDAGLV, paired with TB-500 as full-length thymosin β4, the mature N-acetylated 43-residue peptide Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES-OH. The seven-residue Ac-LKKTETQ fragment is a different molecule and is not this component. Separate preclinical findings do not establish the performance of a co-presented material. The 2021 retrospective knee report contacted 16 of 17 patients and included only four recipients of BPC-157 plus material described as thymosin beta-4/TB4; it was uncontrolled and did not characterize that material. It therefore does not prove efficacy, compatibility or synergy for this catalogue pairing. Exact physical presentation must be confirmed per quote and released lot.
Component-level identity and assay development, controlled in-vitro pathway comparisons, cell-migration or matrix-remodelling hypotheses, and mixture-specific analytical/stability research
These are laboratory applications, not treatment indications.
Mechanism context
The question the literature is testing
BPC-157 literature proposes effects involving nitric-oxide signalling, endothelial pathways and growth-factor expression. Full-length thymosin β4 sequesters G-actin through its LKKTETQ region and is studied in cell-migration and repair models. Complementary mechanisms are a hypothesis, not demonstrated synergy. Component identity, concentration, ratio, matrix and orthogonal controls must be defined directly.
Dose / exposure contextProtocol-specific; verify the cited primary source
Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.
Evidence boundaries
Compatibility, limitations and decision context
Not for human or veterinary use
Neither separate preclinical findings nor a small uncontrolled retrospective report establishes safety of the combination
Chemical purity does not establish sterility, bacterial-endotoxin control, injectable suitability or clinical compatibility
BPC-157 is prohibited under WADA S0 and TB-500/thymosin-β4 derivatives under WADA S2
Follow each component SDS and institutional controls.
Interactions reported in the literature
No validated drug-interaction or combination-safety data exist for this pairing
Vendor “synergy,” stacking, anticoagulant, chemotherapy and other patient-medication lists are not controlled evidence and are not provided as clinical guidance.
Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.
Batch documentation
BPC-157 + TB-500 (Wolverine Stack) batch COAs
Laboratory: Manufacturer's QC laboratoryTests: HPLC purity · MS identity · endotoxin · fill amount
10 mg
20 mg
30 mg
Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.
Published COAs show recent representative batches and may not be the newest. For a quote or shipment, sales confirms the lot and sends its COA.
Third-party reports, added progressively
Previews of the first page of third-party reports are on our Quality page and on the matching product pages; sales sends the full report on request. You can also send any vial from your order to an independent laboratory of your choice. Unless agreed otherwise in writing, the buyer pays for optional testing.
Help reviewing your COA
Need help reading a batch COA or third-party report? Sales can explain the test items, specifications and how the results relate to the lot under discussion.
On every batch COA: HPLC purity · MS identity · endotoxin · fill amount · Verify LyoPep
Third-party reports for BPC-157 + TB-500 (Wolverine Stack)
Reports from Qorix (tjqxgd.com), a third-party analytical laboratory in Tianjin, China: HPLC purity and MS identity of the sample tested.
Laboratory: Third-party laboratoryTests: HPLC purity · MS identity
10 mg
Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.
Ask for the current packet, not a generic certificate
If co-presented, also require methods that resolve both components and relevant impurities, ratio and content-uniformity results, mixture-specific stability and container-closure evidence
Sterility and bacterial endotoxin are separate released attributes; appearance or a blended HPLC percentage is insufficient.
Batch COA for the released lotHPLC purity with method contextMS identity resultEndotoxin resultFill amount (measured content per vial)SDS and handling statement
Available fills
Quote the fill and pack configuration you need
Reference SKUFillBase pack
BB1010 mg10 vials
BB2020 mg10 vials
BB3030 mg10 vials
Handling
Plan storage before the parcel arrives
Use only the released-lot COA, SDS and stability statement for the actual presentation. If separate, qualify each component independently; if co-presented, require mixture-specific stability, compatibility, concentration, matrix, container and hold-time evidence. Do not apply a generic 2–8°C or 30-day rule.
State the destination and timing so receipt can be planned, then move the material into its stated storage condition on arrival.
Buyer FAQ
Terms to settle before the purchase order
Can a buyer arrange third-party testing?+
Yes. You can send any vial from your order to an independent laboratory of your choice. If you want the laboratory, specification, sampling, method and acceptance rule agreed with us before testing, sales confirms them in writing. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.
What if my own lab test shows the product is out of specification?+
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
Does HPLC purity prove peptide content?+
No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.
How should material be stored after delivery?+
Move it into the storage condition stated on the batch COA or label as soon as it arrives, and record the package condition on receipt.
How are payment terms handled?+
Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.
Why must the testing laboratory understand peptide chemistry?+
Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.
These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.
Selected sources
Literature behind the research context
Identity: PubChem CID 9941957 for BPC-157 and PubChem CID 16132341 for full-length thymosin β4. Evidence boundary: Lee and Padgett 2021, PMID 34324435, was a small uncontrolled retrospective report; its combination arm was described as BPC-157 plus thymosin beta-4/TB4. Pharmacokinetic context: Frontiers in Pharmacology 2022, PMCID PMC9794587, reports animal BPC-157 values only. Regulatory context: FDA's current compounding-safety page, staff briefing materials for the scheduled July 23–24, 2026 PCAC meeting and the official 2026 WADA Prohibited List. None of these sources validates the marketed two-peptide pairing.
01
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing
Current Reviews in Musculoskeletal Medicine · 2025 · narrative review (peer-reviewed)
Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry
Journal of Chromatography A · 2012 · peer-reviewed original research (analytical/regulatory)
Questions buyers ask about BPC-157 + TB-500 (Wolverine Stack)
Does separate evidence for BPC-157 and TB-500 prove synergy of the pairing?+
No. BPC-157 and full-length thymosin-β4 (TB-500) have different proposed biology, but no identified controlled peer-reviewed study established additive efficacy, synergy, compatibility or safety for the marketed pairing. The small retrospective knee report described its combination material only as thymosin beta-4/TB4 and was uncontrolled; it therefore cannot validate this material. Combination hypotheses require direct controls against each component and the vehicle.
Does a variant label prove that the two peptides are co-lyophilized at the stated ratio?+
No. Nominal labels such as 5 mg + 5 mg describe requested component amounts but do not prove physical presentation, actual content, uniformity or stability. The quote, container record and released-lot COA must state whether components are separate or co-presented, the content acceptance range for each component, blend or fill-uniformity evidence and the test method.
Which analytical controls are required for a two-peptide material?+
Require each component’s exact sequence, termini, salt/counterion, theoretical and observed intact mass, sequence evidence, stability-indicating chromatography and quantitative peptide content. For co-presented material, methods must also resolve both components and relevant impurities, verify ratio and content uniformity, and support mixture-specific stability. A generic HPLC area percentage or a single mass trace cannot qualify both peptides.
